CHAPEL HILL, N.C. - iOrganBio, an innovator in intelligent cell manufacturing, announced the appointment of Jessica Owens to its Board of Directors. Owens, a seasoned venture investor and serial founder with over 20 years of experience at the intersection of life sciences, health technology, and AI, co-founded GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson. She also co-founded Initiate Ventures and serves as General Partner there.
iOrganBio stated that Owens' counsel will be invaluable as the company scales its CellForge platform, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. The appointment underscores iOrganBio's commitment to integrating AI and engineering precision into biology for consistent, scalable production of human cells and organoids for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs).
Owens' background in building and scaling companies in life sciences and AI aligns with iOrganBio's mission to redefine how human cells are engineered and produced at scale. Her experience with GRAIL, a company that developed multi-cancer early detection tests, and her work at Initiate Ventures, which invests in early-stage life sciences and AI companies, provide her with a unique perspective on the challenges and opportunities in bringing advanced technologies to market.
iOrganBio's CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. The platform is supported by the company's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver the accuracy, efficiency, and quality needed for disease modeling, regenerative medicine, and drug development.
For more information, visit iOrgan.Bio or follow on LinkedIn.
